Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J gets $260 mln talc verdict overturned in Oregon, new trial ordered
01:26pm, Monday, 16'th Sep 2024
An Oregon judge has overturned a $260 million verdict against Johnson & Johnson in a lawsuit brought by a woman who said she got mesothelioma, a deadly cancer linked to asbestos exposure, from inhalin
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Monday, 16'th Sep 2024
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Millionaire Style: Smart Dividend Ideas For Big Returns
07:30am, Monday, 16'th Sep 2024
The ultra-wealthy invest in assets like stocks, real estate, and businesses. These strategies can provide insight into how everyday investors can build lasting wealth. In today's uncertain market, foc
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, Spain , Sept. 16, 202
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCE
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
09:45am, Saturday, 14'th Sep 2024
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer BARCELONA , Sept. 1
Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NY
Johnson & Johnson: A Strategic MedTech Shift For This Dividend King
10:10am, Friday, 13'th Sep 2024
Ongoing lawsuits have presented the opportunity. It is up to the investor to decide just how much risk this adds to the thesis. Post Kenvue spin, the company is deciding to use cash to further diversi
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
12:41pm, Thursday, 12'th Sep 2024
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
How To Earn $500 A Month From Johnson & Johnson Stock
08:33am, Thursday, 12'th Sep 2024
On Tuesday, Johnson & Johnson JNJ announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions
Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies
Chief Future Officer: Joseph Wolk, Johnson & Johnson Executive VP & CFO
09:49pm, Wednesday, 11'th Sep 2024
Chief Financial Officers now play a critical role in shaping corporate strategy and positioning organizations to meet future challenges. Bloomberg's monthly program, Chief Future Officer, profiles the
J&J CFO Sees Value in Tech Partnerships
09:35pm, Wednesday, 11'th Sep 2024
Medical Technology has become a high-growth segment within the health care industry, while opening up new possibilities in patient care. On Bloomberg Chief Future Officer, Johnson & Johnson CFO Joe Wo
How J&J's CFO Keeps His Footing on the 'Patent Cliff'
09:35pm, Wednesday, 11'th Sep 2024
Between 2024 and 2030, the largest US pharma companies will lose patent protections on drugs that now account for $180 billion in sales. Johnson & Johnson has $15 billion in sales at risk of erosion.
US FDA expands J&J's psoriasis drug for inflammatory bowel disease
06:35pm, Wednesday, 11'th Sep 2024
The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said on Wednesda
